Literature DB >> 11062153

SULT1A1 catalyzes 2-methoxyestradiol sulfonation in MCF-7 breast cancer cells.

B C Spink1, B H Katz, M M Hussain, S Pang, S P Connor, K M Aldous, J F Gierthy, D C Spink.   

Abstract

In a previous study of nine human breast-derived cell lines, rates of metabolism of 17beta-estradiol (E(2)) were greatly enhanced when cultures were exposed to the aromatic hydrocarbon receptor agonist, 2,3,7,8-tetrachlorodibenzo-p-dioxin. Elevated rates of E(2) hydroxylation at the C-2, -4, -6alpha and -15alpha positions were observed concomitant with the induction of cytochromes P450 1A1 and 1B1. In each cell line, 2- and 4-hydroxyestradiol (2- and 4-OHE(2)) were converted to 2- and 4-methoxyestradiol (2- and 4-MeOE(2)) by the action of catechol O:-methyltransferase. In this study, conjugation of these estrogen metabolites was investigated. A comparison of the levels of metabolites determined with and without prior treatment of the media with a crude beta-glucuronidase/sulfatase preparation showed that most of the 2-MeOE(2) present was in conjugated form, whereas 4-MeOE(2), 6alpha-OHE(2) and 15alpha-OHE(2) were minimally conjugated. Inhibitor studies suggested that it was the sulfatase activity of the preparation that hydrolyzed the 2-MeOE(2) conjugates in MCF-7 cell media; the presence of 2-MeOE(2)-3-sulfate in MCF-7 culture media was confirmed by electrospray ion-trap mass spectrometry. To identify the enzyme catalyzing this conjugation, the expression of mRNAs encoding five sulfotransferases (SULT1A1, SULT1A2, SULT1A3, SULT1E1 and SULT2A1) was evaluated in the nine cell lines by use of the reverse transcription-polymerase chain reaction. Only expression of SULT1A1 mRNA correlated with the observed conjugation of nanomolar levels of 2-MeOE(2) in these cell lines. Cloning and sequencing of SULT1A1 cDNA from MCF-7 cells revealed that mRNAs encoding two previously identified allelic variants, SULT1A1*1 ((213)Arg) and SULT1A1*2 ((213)His), were expressed in these cells. Heterologous cDNA-directed expression of either variant in MDA-MB-231 cells, which do not normally express SULT1A1, conferred 2-MeOE(2) sulfonation activity. The SULT1A1 allelic variants were also expressed in SF:9 insect cells, from which post-microsomal supernatants were used to determine K:(m) values of 0.90 +/- 0.12 and 0.81 +/- 0.06 microM for SULT1A1*1 and SULT1A1*2, respectively, with 2-MeOE(2) as substrate. These results show that SULT1A1 is an efficient and selective catalyst of 2-MeOE(2) sulfonation and, as such, may be important in modulating the anticarcinogenic effects of 2-MeOE(2) that have been described recently.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062153     DOI: 10.1093/carcin/21.11.1947

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  16 in total

1.  Expression of the aryl hydrocarbon receptor is not required for the proliferation, migration, invasion, or estrogen-dependent tumorigenesis of MCF-7 breast cancer cells.

Authors:  Barbara C Spink; James A Bennett; Nicole Lostritto; Jacquelyn R Cole; David C Spink
Journal:  Mol Carcinog       Date:  2012-03-02       Impact factor: 4.784

2.  Intratumoral estrogen sulfotransferase induction contributes to the anti-breast cancer effects of the dithiocarbamate derivative TM208.

Authors:  Xi-wei Ji; Guang-ping Chen; Yan Song; Ming Hua; Li-jie Wang; Liang Li; Yin Yuan; Si-yuan Wang; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2015-05-04       Impact factor: 6.150

Review 3.  Sulfotransferase genetic variation: from cancer risk to treatment response.

Authors:  Jaclyn Daniels; Susan Kadlubar
Journal:  Drug Metab Rev       Date:  2013-09-06       Impact factor: 4.518

4.  Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.

Authors:  Mellissa Yong; Stephen M Schwartz; Charlotte Atkinson; Karen W Makar; Sushma S Thomas; Katherine M Newton; Erin J Aiello Bowles; Victoria L Holt; Wendy M Leisenring; Johanna W Lampe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

5.  Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion.

Authors:  Erika Terzuoli; Maura Puppo; Annamaria Rapisarda; Badarch Uranchimeg; Liang Cao; Angelika M Burger; Marina Ziche; Giovanni Melillo
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

Review 6.  Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges.

Authors:  Svetlana Verenich; Phillip M Gerk
Journal:  Mol Pharm       Date:  2010-10-21       Impact factor: 4.939

7.  Resveratrol protects the ovary against chromium-toxicity by enhancing endogenous antioxidant enzymes and inhibiting metabolic clearance of estradiol.

Authors:  Sakhila K Banu; Jone A Stanley; Kirthiram K Sivakumar; Joe A Arosh; Robert C Burghardt
Journal:  Toxicol Appl Pharmacol       Date:  2016-04-27       Impact factor: 4.219

8.  Induction of CYP1A1 and CYP1B1 by benzo(k)fluoranthene and benzo(a)pyrene in T-47D human breast cancer cells: roles of PAH interactions and PAH metabolites.

Authors:  David C Spink; Susan J Wu; Barbara C Spink; Mirza M Hussain; Dilip D Vakharia; Brian T Pentecost; Laurence S Kaminsky
Journal:  Toxicol Appl Pharmacol       Date:  2007-09-05       Impact factor: 4.219

9.  Expression and functional activities of selected sulfotransferase isoforms in BeWo cells and primary cytotrophoblast cells.

Authors:  Pallabi Mitra; Kenneth L Audus
Journal:  Biochem Pharmacol       Date:  2009-07-30       Impact factor: 5.858

10.  SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites.

Authors:  L P Madhubhani P Hemachandra; Hitisha Patel; R Esala P Chandrasena; Jaewoo Choi; Sujeewa C Piyankarage; Shuai Wang; Yijin Wang; Emily N Thayer; Robert A Scism; Bradley T Michalsen; Rui Xiong; Marton I Siklos; Judy L Bolton; Gregory R J Thatcher
Journal:  Cancer Prev Res (Phila)       Date:  2014-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.